



GEDEON RICHTER

Celebrating 125 years

## Richter and Acrux agree to license Lenzetto® for Australia

**Budapest, Hungary and Melbourne, Australia; 27 May 2026** – Gedeon Richter Plc. (“Richter”) and Acrux Limited (“Acrux”) today announce the extension of the license agreement dated 2 May 2013 relating to the transdermal Estradiol spray, Lenzetto®, a menopause hormone therapy to cover an additional commercially significant territory. The amended agreement provides Richter exclusive commercialization rights for the Australian market. Acrux will receive total payments of AUD 5.4mn over the coming period, including an upfront payment and regulatory and commercial milestones.

### About Lenzetto®

Lenzetto® was developed by Acrux and is already licensed to and marketed by Richter in more than 40 countries worldwide with total sales of EUR 50mn in 2025. Lenzetto® is a transdermal Estradiol spray, a hormone replacement therapy (HRT) treatment of symptoms, such as hot flashes, associated with estrogen deficiency occurring in women after menopause. Estradiol is delivered by a unique Patchless Patch™ technology, which was invented at the Monash University and has helped to change the lives of millions of women worldwide.

### About Richter

Richter aspires to be a global innovator in some key scientific fields, while dedicated to making medicines more accessible worldwide. Founded in 1901, headquartered in Hungary, with a market capitalization of EUR 4.8bn and sales of EUR 2.3bn in 2025, it operates Central Europe’s largest R&D hub. Its research drives breakthroughs in Neuropsychiatry and Women’s Healthcare, while Biotechnology and General Medicines strengthen its affordable treatment portfolio. Committed to sustainable growth, Richter invests in R&D, manufacturing excellence, and digitalization to advance medical innovation. Learn more at [www.gedeonrichter.com](http://www.gedeonrichter.com)

### About Acrux

Acrux Limited (ASX:ACR) is a specialty pharma company with a successful track record of developing and commercializing a pipeline of topically applied pharmaceutical products. Drawing on 25 years of experience, Acrux has successfully marketed through licensees a number of products worldwide with emphasis on the United States.

### For further information:

Investors: Róbert Réthy, CFA  
Media: Zsuzsa Beke

+36 20 342 2555  
+36 20 916 4507

Chemical Works of Gedeon Richter Plc.

Headquarters: H-1103 Budapest, Gyömrői út 19-21., Hungary • Postal address: H-1475 Budapest 10., Pf. 27., Hungary

Phone: +36 1 431 4000 • Company Court of Budapest-Capital Tribunal Reg. No. Cg. 01-10-040944

EU Community VAT Identification No: HU 10484878 • [www.gedeonrichter.com](http://www.gedeonrichter.com)